Skip to main content

Advertisement

Table 1 Patient demographics and baseline characteristics

From: A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery

  SRI MiRI
Edoxaban 15 mg Edoxaban 15 mg Fondaparinux 1.5 mg Edoxaban 30 mg
CL CR (mL/min) ≥15 to <20 ≥20 to <30 ≥20 to <30 ≥50 to ≤80
N = 7 N = 22 N = 20 N = 30
Female, n (%) 6 (85.7) 19 (86.4) 20 (100.0) 27 (90.0)
Age, yr     
mean (SD) 91.7 (7.1) 86.5 (4.3) 85.7 (8.9) 78.1 (6.5)
 <75, n (%) 0 0 2 (10.0) 8 (26.7)
 ≥75, n (%) 7 (100.0) 22 (100.0) 18 (90.0) 22 (73.3)
Weight, kg     
mean (SD) 39.4 (3.8) 44.3 (8.9) 46.1 (8.0) 54.5 (11.1)
 ≤60, n (%) 7 (100.0) 21 (95.5) 18 (90.0) 22 (73.3)
 >60, n (%) 0 1 (4.5) 2 (10.0) 8 (26.7)
CLCR, mL/min     
median 18.7 27.6 26.2 62.7
min–max 15.3–20.0 20.4–30.0 22.8–30.0 50.7–79.8
Surgery, n (%)     
 TKA 0 5 (22.7) 6 (30.0) 9 (30.0)
 THA 0 1 (4.5) 4 (20.0) 8 (26.7)
 HFS 7 (100.0) 16 (72.7) 10 (50.0) 13 (43.3)
Physiotherapy use, n (%)     
 Present 7 (100.0) 22 (100.0) 20 (100.00) 30 (100.0)
  Elastic stocking 7 (100.0) 21 (95.5) 19 (95.0) 23 (76.7)
  Intermittent pneumatic compression 5 (71.4) 8 (36.4) 9 (45.0) 19 (63.3)
Concomitant use of NSAIDs, n (%) 6 (85.7) 20 (90.9) 18 (90.0) 29 (96.7)
Concomitant use of P-gp inhibitor, n (%) 1 (14.3) 0 (0.0) 0 (0.0) 1 (3.3)
  1. CLCR = creatinine clearance (calculated using the Cockcroft-Gault formula); HFS = hip fracture surgery; MiRI = mild renal impairment; NSAIDs = nonsteroidal anti-inflammatory drugs; P-gp = P-glycoprotein; SRI = severe renal impairment; THA = total hip arthroplasty; TKA = total knee arthroplasty.